Literature DB >> 33341430

Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges.

Zhengnan Yang1, Ryan C Gimple2, Nianxin Zhou1, Linjie Zhao3, Jan-Åke Gustafsson4, Shengtao Zhou5.   

Abstract

Nuclear receptors are a family of transcription factors localized in cell nuclei, sensing specific ligands and fine-tuning a variety of cell physiological events. They have been intensively investigated in cancer biology. With their excellent properties of druggability and actionability, nuclear receptors have demonstrated much promise as novel therapeutic targets for different cancer types. Accumulating evidence has highlighted the essential roles of certain nuclear receptors in tumor immunology, suggesting the possibility for them to serve as cancer immunotherapeutic targets. Here, we summarize the roles of nuclear receptors in cancer biology and tumor immunology, and underscore the current advances of clinical trials for nuclear receptor-based cancer therapeutics.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer therapy; nuclear receptors; tumor immunology

Mesh:

Substances:

Year:  2020        PMID: 33341430     DOI: 10.1016/j.trecan.2020.11.007

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  2 in total

1.  TRIB3 Modulates PPARγ-Mediated Growth Inhibition by Interfering with the MLL Complex in Breast Cancer Cells.

Authors:  Miguel Hernández-Quiles; Rosalie Baak; Alba Orea-Soufi; Anouska Borgman; Suzanne den Haan; Paula Sobrevals Alcaraz; Aldo Jongejan; Robert van Es; Guillermo Velasco; Harmjan Vos; Eric Kalkhoven
Journal:  Int J Mol Sci       Date:  2022-09-11       Impact factor: 6.208

2.  A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.

Authors:  Manuela Cipolletti; Stefania Bartoloni; Claudia Busonero; Martina Parente; Stefano Leone; Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.